The Board of Directors ofEXACT Therapeutics AS wishes to accommodate the liquidity of the shares of EXACT Therapeutics and the Board has decided to propose a share split as further described below. The proposal will be presented for approval at the EGM on24 July 2020 . Date on which the corporate action is made public:16 July 2020 Split ratio: 1 old share will give 250 new shares Last day inclusive right to have 1 share traded into 250 shares:24 July 2020 (being the date of the EGM) Ex-date: 27 July Record date:28 July 2020 Date of approval:24 July 2020 For further queries, please contact:Masha Stromme , Chair +47 93022509Stig Jarle Pettersen , CFO +47 90960336 EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com
Click here for more information
© Oslo Bors ASA, source